Location: Home /  Customer Resources

MGI Statement

Release date:2020-08-18Writer:MGIViews:1094Share

Regarding the patent lawsuit initiated by Illumina against MGI in Hong Kong, the specific impact has yet to be determined.


MGI believes that this patent litigation is an obvious attempt by Illumina to maintain a monopolistic market position and suppress the development of the industry. We intend to vigorously defend our intellectual property, and we have filed patent litigation against Illumina in U.S. District Court in California and Delaware.


MGI has an extensive patent portfolio in the field of gene sequencing, and its original intention has been to "provide the world with the right to another choice." MGI will continue to provide effective and affordable healthcare technologies and products for all.

  • Hotline (Global)
    +86-4000-688-114
  • Email
    MGI-service@mgi-tech.com
  • Special Recommendations
  • *For research use only.

    Not for use in diagnostic procedures (except as specifically noted).
Copyright © 2024 All Rights Reserved MGI Tech Co., Ltd. Guangdong ICP 16117185Privacy PolicyLegal NoticesCookie Policy
Our use of cookies
We would like to use necessary cookies to improve your browsing experience and the quality of our website. We would also like to set analytics cookies and advertisement cookies that help us make improvements by measuring how you use our website. Detailed information about the use of cookies on this website and how you can control your consent can be found in our Cookie Policy and Privacy Policy.
Accept only strictly necessary cookiesAccept all cookies